mortality/aging
• progressive after pIpC treatment
|
hematopoietic system
• pIpC-treated mice exhibit bone marrow failure that is hemopoeitic-specific and cell-autonomous
|
• in the bone marrow of pIpC-treated mice
|
• progressive after pIpC treatment
|
• in the bone marrow of pIpC-treated mice
|
• in the bone marrow and spleen of pIpC-treated mice
|
• in the bone marrow of pIpC-treated mice
|
• in pIpC-treated mice
|
polycythemia
(
J:192124
)
• in the bone marrow of pIpC-treated mice at the time of death
|
• in pIpC-treated mice
|
• in pIpC-treated mice
|
• in pIpC-treated mice
|
• in the blood and bone marrow of pIpC-treated mice
|
• in pIpC-treated mice
|
• B cell and B-type progenitors in the bone marrow of pIpC-treated mice
|
• in the bone marrow and spleen of pIpC-treated mice
|
• in pIpC-treated mice
|
• virtual absence of short and long term hematopoietic stem cells (HSCs) in the bone marrow of pIpC-treated mice
• progressive 11-fold decrease as early as 12 days after pIpC treatment
• decreased LT-HSCs in the spleens of pIpC-treated mice
|
• reduced proliferation of long term HSCs, myeloid progenitors, and total bone marrow cells in pIpC-treated mice
• increased apoptosis of myeloid progenitors in pIpC-treated mice
|
• 9-fold decrease in hematopoietic stem cell mobilization to the spleen in pIpC-treated mice
|
• in long term HSCs of pIpC-treated mice
|
immune system
• in pIpC-treated mice
|
• in the blood and bone marrow of pIpC-treated mice
|
• in pIpC-treated mice
|
• B cell and B-type progenitors in the bone marrow of pIpC-treated mice
|
• in the bone marrow and spleen of pIpC-treated mice
|
• in pIpC-treated mice
|
cellular
• in long term HSCs of pIpC-treated mice
|